Advance Pharma GmbH, Berlin, is a manufacturer of oral, solid human dosage forms and holds a manufacturing authorization pursuant to § 13 AMG from the Berlin State Office for Health and Social Affairs. It primarily operates as a contract manufacturer without its own approvals for renowned pharmaceutical companies from Germany and other European countries as well as for affiliated companies of the Aristo group. In addition to pharmaceuticals, the company also produces related products such as dietary supplements and dietetic foods. Advance Pharma is part of the Aristo Pharma group and is consolidated in the group financial statements; in fiscal year 2019 it employed an average of 222 employees.
Die Herstellung von pharmazeutischen und kosmetischen Erzeugnissen sowie Nahrungsergänzungsmitteln aller Art.
Converted using the official Destatis and Eurostat correspondence tables; ISIC Rev. 4 is the United Nations' international industry classification.
This summary was generated with the help of AI. See our Data Quality Notice. Report error?
Source: German Commercial Register (Handelsregister) Berlin (Charlottenburg) Local Court, HRB 110933 (as of 30 October 2026)
| Name | Type | City |
|---|---|---|
| Christian Jaaks | Geschäftsführer(in) | Berlin |
| Guido Zimmermann | Geschäftsführer(in) | Düsseldorf |
Source: German Commercial Register (Handelsregister) Berlin (Charlottenburg) Local Court, HRB 110933 (as of 30 October 2026)
| Year | Revenue | Profit | Balance | Employees |
|---|---|---|---|---|
| 2019 | Rohergebnis€12.8M2 | -€7,335,415 | €39,981,487 | — |
| 2018 | Rohergebnis€13.4M2 | -€3,130,251 | €35,124,469 | — |
| 2017 | Rohergebnis€13.2M2 | €1,664,054 | €22,482,758 | — |
| 2016 | Rohergebnis€10.5M2 | €1,833,181 | €17,815,729 | — |
| 2015 | Rohergebnis€11.8M2 | -€1,324,813 | €12,716,361 | — |
| 2014 | Rohergebnis€15.2M2 | €485,219 | €16,228,152 | — |
| 2013 | Rohergebnis€02 | -€1,334,733 | €15,719,977 | — |
| 2012 | Rohergebnis€13M2 | €645,246 | €11,532,249 | — |
| 2011 | Rohergebnis€12.1M2 | -€2,134,133 | €13,337,543 | — |
| 2010 | Rohergebnis€12M2 | -€2,379,977 | €13,604,058 | — |
1 Small companies are not required to publish a profit-and-loss statement (§ 326 (1) HGB). The figure shown is the statutory ceiling under § 267 HGB where the balance-sheet total makes it binding — a company may exceed at most one of the three size criteria.
2 Rohergebnis nach § 276 HGB: Umsatzerlöse abzüglich Materialaufwand bzw. Herstellungskosten. Kleine und mittelgroße Kapitalgesellschaften dürfen diese Posten zusammenfassen; die Umsatzerlöse selbst sind dann nicht veröffentlicht und liegen über dem Rohergebnis.
Sign in to download data
Source: German Commercial Register (Handelsregister) Berlin (Charlottenburg) Local Court, HRB 110933 (as of 30 October 2026)
| Cost type | Amount | Share |
|---|---|---|
| Personnel Costs | €9,985,071 | 74.4% |
| Depreciation | €2,615,369 | 19.5% |
| Interest & Similar | €820,499 | 6.1% |
